Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 14/20 | 0.65 |
| ▸ | SLC10A2 | Q12908 | 1/20 | 0.53 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.53 |
| ▸ | SLC10A6 | Q3KNW5 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | BCL2 | P10415 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7213171 | 0.90 | EDNRA (0.53) | EDNRASLC10A2SLC10A1SLC10A6HDAC1 | |
| SCHEMBL7128469 | 0.80 | SLC10A2 (0.60) | SLC10A2SLC10A1SLC10A6 | |
| SCHEMBL7213174 | 0.78 | SLC10A6 (0.61) | EDNRASLC10A2SLC10A1SLC10A6 | |
| SCHEMBL7117455 | 0.78 | SLC10A2 (0.60) | SLC10A2SLC10A1SLC10A6 | |
| SCHEMBL7209345 | 0.77 | SLC10A2 (0.52) | SLC10A2SLC10A1SLC10A6 | |
| SCHEMBL7128140 | 0.76 | SLC10A6 (0.61) | SLC10A2SLC10A1SLC10A6 | |
| SCHEMBL28748521 | 0.76 | EDNRA (0.45) | EDNRA | |
| SCHEMBL7116008 | 0.75 | SLC10A6 (0.85) | SLC10A2SLC10A1SLC10A6 | |
| SCHEMBL27575113 | 0.75 | SLC10A6 (0.56) | SLC10A2SLC10A1SLC10A6 | |
| SCHEMBL7065506 | 0.75 | EDNRA (0.70) | EDNRAHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1187531-A4 | MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2003-05-28 | — | — | EP | claimed |
| US-6458845-B1 | METHOD OF ANTAGONIZING A MACROPHAGE SCAVENGER RECEPTOR COMPRISING ADMINISTERING TO A SUBJECT IN NEED OF TREATMENT AN EFFECTIVE AMOUNT OF AN N-PHENYL-2-(3-TRIFLUOROMETHYLPHENYLSULFONAMIDO)BENZAMIDE, A | SMITHKLINE BEECHAM CORPORATION | 2002-10-01 | — | — | US | claimed |
| EP-1187531-A1 | MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2002-03-20 | — | — | EP | claimed |
| WO-2001098264-A1 | MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-12-27 | — | — | WO | claimed |
| WO-2000078145-A1 | MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-12-28 | — | — | WO | claimed |
| US-6458845-B1 | METHOD OF ANTAGONIZING A MACROPHAGE SCAVENGER RECEPTOR COMPRISING ADMINISTERING TO A SUBJECT IN NEED OF TREATMENT AN EFFECTIVE AMOUNT OF AN N-PHENYL-2-(3-TRIFLUOROMETHYLPHENYLSULFONAMIDO)BENZAMIDE, A | SMITHKLINE BEECHAM CORPORATION | 2002-10-01 | — | — | US | disclosed |
| WO-2001098264-A1 | MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-12-27 | — | — | WO | disclosed |